A Certificate of Analysis (COA) is a formal quality document issued by a manufacturer certifying that a specific lot of material has been tested against defined specifications and the results recorded. For synthetic research peptides, a COA typically covers identity, purity, physical appearance, moisture content, endotoxin level, and release authorization. The following guide describes each field in the context of a Nexphoria lot release document.
1.0 Header Fields
Header fields uniquely identify the document, the material, and the manufacturing event. All COA header fields are subject to document control and must be verified before using any analytical result.
| Compound Name | Full descriptor as used in the product catalog. May include common name and systematic abbreviation. |
|---|---|
| Lot Number | Unique batch identifier in Nexphoria format NX-YYMM-NNN (see Lot Numbering Convention note). Cross-references to synthesis batch and purification records. |
| Manufacture Date | Date on which the synthesis batch was completed and passed in-process testing. Format: YYYY-MM-DD. |
| Expiry Date | Date through which the material is guaranteed to meet specification under stated storage conditions. Calculated from real-time stability data per ICH Q1A(R2). |
| Batch Size | Net mass of lyophilized material released from this lot, in milligrams. |
| CAS Number | Chemical Abstracts Service registry number; confirms chemical identity at document level. |
| Document Number | Internal quality document control number. Referenced in batch record and deviation log if applicable. |
2.0 Identity
Identity testing confirms that the material is the stated compound and not a structurally related impurity, synthetic by-product, or mis-labeled material. Two independent methods are required for unambiguous identity confirmation [1].
| HPLC Retention Time | Retention time (minutes) of the main peak observed in the analytical HPLC run, compared against a certified reference standard. Typical tolerance: ±0.3 min. A retention time match alone is insufficient for identity confirmation. |
|---|---|
| MS Confirmation | Observed average mass (Da) by ESI-MS or MALDI-TOF. Compared against theoretical molecular weight. Acceptance criterion: within ±0.5 Da (ESI) or ±1 Da (MALDI) of theoretical. Deconvoluted mass must match the stated compound sequence. |
| Identity Result | Pass / Fail declaration. Both HPLC retention time and MS confirmation must individually pass; a compound that passes only one criterion is not released. |
3.0 Purity
Purity is determined by reversed-phase HPLC with UV detection at 220 nm. At this wavelength, the peptide backbone (amide bonds) absorbs uniformly, providing a near-universal response for peptide quantification regardless of amino acid composition. Results are reported as area percent of the main peak [2].
| Main Peak (%) | Area percent of the largest chromatographic peak, which corresponds to the target compound. Specification: ≥98% for lot release. Values between 95–98% require QA review. |
|---|---|
| Impurity Profile | All peaks exceeding 0.1% area are reported individually. Peaks below 0.1% are summed as "unidentified impurities." The sum of all non-main peaks must not exceed 2.0% for a released lot. |
| Detection Wavelength | 220 nm. Note that aromatic-residue-containing peptides may show supplementary runs at 280 nm; these are reported informatively and do not replace the 220 nm primary purity determination. |
| Column | C18, 4.6×250 mm, 5 µm particle size. Gradient: 5–60% acetonitrile in 0.1% TFA over 25 minutes at 1.0 mL/min, 30°C. |
4.0 Content
Content tests characterize the material beyond purity: how much of the net mass is water, and what is the actual peptide mass fraction. Both determinations are required to calculate accurate working concentrations.
| Moisture (Karl Fischer) | Water content by coulometric Karl Fischer titration (USP <921>). Reported as % w/w. Acceptance criterion: ≤6.0% w/w. Lyophilized peptides routinely contain 3–5% residual moisture; values below 2% may indicate over-drying that can affect dissolution. |
|---|---|
| Peptide Content (AAA) | Amino acid analysis (AAA) by acid hydrolysis (6 N HCl, 110°C, 24 h) followed by derivatization and HPLC quantitation. Reports actual peptide mass fraction as a percentage of total net weight. Used to calculate true peptide content per vial. |
| Net Weight | Gravimetric determination (calibrated analytical balance, ±0.01 mg). Reported per vial and per lot. |
5.0 Endotoxin
Endotoxin testing detects lipopolysaccharide (LPS) from gram-negative bacterial cell walls. Endotoxin contamination can originate from synthesis reagents, resin, water, or equipment. The limulus amebocyte lysate (LAL) kinetic-chromogenic assay is the standard method per USP <85> [3].
| Method | LAL kinetic-chromogenic assay, USP <85>. Recombinant Factor C (rFC) assay may be substituted when scientifically justified. |
|---|---|
| Units | Endotoxin Units per milligram (EU/mg). One EU is approximately 0.1–0.2 ng of E. coli LPS reference standard. |
| Acceptance Criterion | ≤0.5 EU/mg. This criterion is derived from the research-use standard; parenteral drug products are held to ≤0.2 EU/kg/h (USP <85> context). |
| Reported Value | Observed EU/mg with 95% confidence interval. Spike recovery (positive product control) must be within 50–200% per USP <85> to validate the result against matrix interference. |
6.0 Appearance
Visual appearance is assessed under standardized daylight-equivalent illumination (≥2000 lux) against a white and black background. Any deviation from the specification must be investigated before lot release [4].
| Specification | White to off-white lyophilized powder, free of visible foreign matter and particulates. |
|---|---|
| Yellow or beige coloration | May be within specification for certain peptides containing aromatic residues (Trp, Tyr, His). Recorded as observed. |
| Clumping or cake structure | A fused cake is acceptable if it disperses readily on addition of diluent; report notes "lyophilization cake, dissolves readily." Hard, insoluble lumps require investigation. |
| Foreign matter | Any visible particle not matching the expected powder matrix triggers rejection and investigation. Particle identity testing (e.g., FTIR microscopy) is documented in the deviation record. |
7.0 Storage Statement
The COA storage statement defines the conditions under which the stated expiry applies. Storage outside these conditions invalidates the expiry date and may require re-testing before use.
| Lyophilized condition | −20°C, protected from light, original sealed vial. Desiccant included in outer packaging. |
|---|---|
| Reconstituted condition | 2–8°C, protected from light, in original or amber container. Duration: per compound-specific stability data (see individual compound monographs). |
| USP reference | USP <659> Packaging and Storage Requirements. |
8.0 Release Statement
The release statement is the formal quality authorization declaring that the lot meets all specifications and is approved for distribution. It must include an authorized signature and date.
| Release Declaration | "This lot has been tested in accordance with the specifications stated above and has been found to comply in all respects." |
|---|---|
| Authorized Signatory | Quality Assurance, Nexphoria. Printed name and signature (wet or digital with audit trail). |
| Release Date | Date of QA authorization. Must be on or after the completion date of all lot release tests. |
| Document Version | Version number of the COA template and test method(s) applied. Referenced in the internal batch record. |
9.0 Sample COA Layout — BPC-157 Lot NX-2604-001
The following table illustrates a representative COA layout with realistic field values for BPC-157 lot NX-2604-001, manufactured April 2026.
Header
| Compound Name | BPC-157 (Body Protection Compound-157) |
|---|---|
| CAS Number | 137525-51-0 |
| Lot Number | NX-2604-001 |
| Manufacture Date | 2026-04-07 |
| Expiry Date | 2028-04-07 |
| Batch Size | 500 mg (lyophilized) |
Identity
| HPLC Retention Time | 14.7 min (ref: 14.6–15.0 min) | PASS |
|---|---|---|
| ESI-MS Observed [M+H]⁺ | 1420.3 Da (theoretical: 1420.5 Da) | PASS |
Purity
| Main Peak (HPLC-UV 220 nm) | 99.1% (spec: ≥98%) | PASS |
|---|---|---|
| Largest Individual Impurity | 0.5% | PASS |
| Sum of Impurities | 0.9% | PASS |
Content
| Moisture (Karl Fischer) | 4.2% w/w (spec: ≤6.0%) | PASS |
|---|---|---|
| Peptide Content (AAA) | 94.1% w/w | PASS |
| Net Weight per Vial | 5.0 mg nominal | — |
Endotoxin & Appearance
| Endotoxin (LAL, USP <85>) | 0.12 EU/mg (spec: ≤0.5 EU/mg) | PASS |
|---|---|---|
| Appearance | White to off-white lyophilized powder; no visible foreign matter | PASS |
Storage & Release
| Storage Condition | −20°C, sealed vial, protected from light (USP <659>) |
|---|---|
| Release Statement | This lot has been tested in accordance with the specifications stated above and has been found to comply in all respects. |
| Released By | Quality Assurance, Nexphoria — 2026-04-09 |
10.0 References
- [1] United States Pharmacopeia (2024). USP <197> Spectrophotometric Identification Tests. In USP–NF. United States Pharmacopeial Convention.
- [2] Snyder L.R., Kirkland J.J., Dolan J.W. (2010). Introduction to Modern Liquid Chromatography, 3rd ed. Wiley, Hoboken, NJ. ISBN: 978-0-470-16754-0. (Reversed-phase HPLC quantitation methodology)
- [3] United States Pharmacopeia (2024). USP <85> Bacterial Endotoxins Test. In USP–NF. United States Pharmacopeial Convention.
- [4] United States Pharmacopeia (2024). USP <790> Visible Particulates in Injections. In USP–NF. United States Pharmacopeial Convention.
- [5] ICH Harmonised Guideline Q6A: Specifications — Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. (1999). International Council for Harmonisation. https://www.ich.org/page/quality-guidelines